Eliminating the latent HIV reservoir by reactivation strategies: Advancing to clinical trials

Human Vaccines and Immunotherapeutics

Volumn 9, Issue 4, 2013, Pages 790-799

  Rasmussen, Thomas A ^a   Tolstrup, Martin ^a   Winckelmann, Anni ^a   Østergaard, Lars ^a   Søgaard, Ole S ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Cure; Experimental research; Histone deacetylase inhibitors; HIV; Immune modulation

Indexed keywords

6 (1,3 DIOXO 1H,3H BENZO[DE]ISOQUINOLIN 2 YL) N HYDROXYHEXANAMIDE; ABACAVIR; AGATOLIMOD; ANTIRETROVIRUS AGENT; APICIDIN; BELINOSTAT; BRYOSTATIN 1; BRYOSTATIN 2; BUTYRIC ACID; DISULFIRAM; ENFUVIRTIDE; ENTINOSTAT; GIVINOSTAT; HISTONE DEACETYLASE INHIBITOR; INTERLEUKIN 2; INTERLEUKIN 7; N (1 BENZYL 4 PIPERIDINYL) 2 (HEXAHYDRO 4 METHYL 1H 1,4 DIAZEPIN 1 YL) 6,7 DIMETHOXY 4 QUINAZOLINAMINE; OKT 3; OXAMFLATIN; PANOBINOSTAT; PLACEBO; PNEUMOCOCCUS VACCINE; RALTEGRAVIR; RECOMBINANT INTERLEUKIN 7; RESIQUIMOD; ROMIDEPSIN; TRICHOSTATIN A; UNINDEXED DRUG; VALPROIC ACID; VORINOSTAT;

ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIVIRAL ACTIVITY; ARTICLE; DRUG ELIMINATION; DRUG POTENCY; DRUG SELECTIVITY; DRUG SPECIFICITY; ENZYME INHIBITION; GRAFT VERSUS HOST REACTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOMODULATION; IMMUNOTHERAPY; LATENT VIRUS INFECTION; NONHUMAN; PERSISTENT VIRUS INFECTION; VIROGENESIS; VIRUS LATENCY; VIRUS REACTIVATION;

CURE; EXPERIMENTAL RESEARCH; HISTONE DEACETYLASE INHIBITORS; HIV; IMMUNE MODULATION;

ANTI-HIV AGENTS; DRUG DISCOVERY; HIV INFECTIONS; HUMANS; VIRUS ACTIVATION; VIRUS LATENCY;

EID: 84877115025     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.23202     Document Type: Article

References (120)

1. Margolis DM. Eradication therapies for HIV Infection: time to begin again. AIDS Res Hum Retroviruses 2011; 27:347-53; PMID:21314240; http://dx.doi.org/10.1089/aid.2011.0017.
2. Palmer S, Maldarelli F, Wiegand A, Bernstein B, Hanna GJ, Brun SC, et al. Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy. Proc Natl Acad Sci U S A 2008; 105:3879-84; PMID:18332425; http://dx.doi.org/10.1073/pnas.0800050105.
3. Palmer S, Wiegand A P, Maldarelli F, Bazmi H, Mican JM, Polis M, et al. New real-time reverse transcriptase-initiated PCR assay with single-copy sensitivity for human immunodeficiency virus type 1 RNA in plasma. J Clin Microbiol 2003; 41:4531-6; PMID:14532178; http://dx.doi.org/10.1128/JCM.41.10. 4531-4536.2003.
4. Finzi D, Blankson J, Siliciano JD, Margolick JB, Chadwick K, Pierson T, et al. Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat Med 1999; 5:512-7; PMID:10229227; http://dx.doi.org/10.1038/8394.
5. Chomont N, El-Far M, Ancuta P, Trautmann L, Procopio FA, Yassine-Diab B, et al. HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation. Nat Med 2009; 15:893-900; PMID:19543283; http://dx.doi.org/10.1038/nm.1972.
6. Hermankova M, Siliciano JD, Zhou Y, Monie D, Chadwick K, Margolick JB, et al. Analysis of human immunodeficiency virus type 1 gene expression in latently infected resting CD4+ T lymphocytes in vivo. J Virol 2003; 77:7383-92; PMID:12805437; http://dx.doi.org/10.1128/JVI.77.13.7383-7392.2003.
7. Kieffer TL, Finucane MM, Nettles RE, Quinn TC, Broman KW, Ray SC, et al. Genotypic analysis of HIV-1 drug resistance at the limit of detection: virus production without evolution in treated adults with undetectable HIV loads. J Infect Dis 2004; 189:1452-65; PMID:15073683; http://dx.doi.org/10.1086/382488.
8. Ellery PJ, Tippett E, Chiu YL, Paukovics G, Cameron PU, Solomon A, et al. The CD16+ monocyte subset is more permissive to infection and preferentially harbors HIV-1 in vivo. J Immunol 2007; 178:6581-9; PMID:17475889.
9. Collman R, Hassan N F, Walker R, Godfrey B, Cutilli J, Hastings JC, et al. Infection of monocyte-derived macrophages with human immunodeficiency virus type 1 (HIV-1). Monocyte-tropic and lymphocyte-tropic strains of HIV-1 show distinctive patterns of replication in a panel of cell types. J Exp Med 1989; 170:1149-63; PMID:2571666; http://dx.doi.org/10.1084/jem.170.4.1149.
10. Sonza S, Mutimer H P, Oelrichs R, Jardine D, Harvey K, Dunne A, et al. Monocytes harbour replication-competent, non-latent HIV-1 in patients on highly active antiretroviral therapy. AIDS 2001; 15:17-22; PMID:11192864; http://dx.doi.org/10.1097/00002030-200101050-00005.
11. Churchill MJ, Wesselingh SL, Cowley D, Pardo CA, McArthur JC, Brew BJ, et al. Extensive astrocyte infection is prominent in human immunodeficiency virus-associated dementia. Ann Neurol 2009; 66:253-8; PMID:19743454; http://dx.doi.org/10.1002/ana.21697.
12. th, Bixby D, Savona MR, et al. HIV-1 infects multipotent progenitor cells causing cell death and establishing latent cellular reservoirs. Nat Med 2010; 16:446-51; PMID:20208541; http://dx.doi.org/10.1038/nm.2109.
13. - naive CD4(+) T cells are persistent HIV type 1-infected reservoirs in individuals receiving antiretroviral therapy. J Infect Dis 2010; 202:1738-48; PMID:20979453; http://dx.doi.org/10.1086/656721.
14. Tran TA, de Goër de Herve MG, Hendel-Chavez H, Dembele B, Le Névot E, Abbed K, et al. Resting regulatory CD4 T cells: a site of HIV persistence in patients on long-term effective antiretroviral therapy. PLoS One 2008; 3:e3305; PMID:18827929; http://dx.doi.org/10.1371/journal.pone.0003305.
15. Josefsson L, Eriksson S, Sinclair E, Ho T, Killian M, Epling L, et al. Hematopoietic precursor cells isolated from patients on long-term suppressive HIV therapy did not contain HIV-1 DNA. J Infect Dis 2012; 206:28-34; PMID:22536001; http://dx.doi.org/10.1093/infdis/jis301.
16. Gandhi RT, Bosch RJ, Aga E, Albrecht M, Demeter LM, Dykes C, et al.; AIDS Clinical Trials Group A5173 Team. No evidence for decay of the latent reservoir in HIV-1-infected patients receiving intensive enfuvirtide-containing antiretroviral therapy. J Infect Dis 2010; 201:293-6; PMID:20001856; http://dx.doi.org/10.1086/649569.
17. Gandhi RT, Zheng L, Bosch RJ, Chan ES, Margolis DM, Read S, et al.; AIDS Clinical Trials Group A5244 team. The effect of raltegravir intensification on low-level residual viremia in HIV-infected patients on antiretroviral therapy: a randomized controlled trial. PLoS Med 2010; 7; PMID:20711481; http://dx.doi.org/10.1371/journal.pmed.1000321.
18. McMahon D, Jones J, Wiegand A, Gange SJ, Kearney M, Palmer S, et al. Short-course raltegravir intensification does not reduce persistent low-level viremia in patients with HIV-1 suppression during receipt of combination antiretroviral therapy. Clin Infect Dis 2010; 50:912-9; PMID:20156060; http://dx.doi.org/10.1086/650749.
19. Dinoso JB, Kim SY, Wiegand AM, Palmer SE, Gange SJ, Cranmer L, et al. Treatment intensification does not reduce residual HIV-1 viremia in patients on highly active antiretroviral therapy. Proc Natl Acad Sci U S A 2009; 106:9403-8; PMID:19470482; http://dx.doi.org/10.1073/pnas.0903107106.
20. Yukl SA, Shergill AK, McQuaid K, Gianella S, Lampiris H, Hare CB, et al. Effect of raltegravir-containing intensification on HIV burden and T-cell activation in multiple gut sites of HIV-positive adults on sup-pressive antiretroviral therapy. AIDS 2010; 24:2451-60; PMID:20827162; http://dx.doi.org/10.1097/QAD.0b013e32833ef7bb.
21. Hammer SM, Ribaudo H, Bassett R, Mellors JW, Demeter LM, Coombs RW, et al.; AIDS Clinical Trials Group (ACTG) 372A Study Team. A randomized, placebo-controlled trial of abacavir intensification in HIV-1-infected adults with virologic suppression on a protease inhibitor-containing regimen. HIV Clin Trials 2010; 11:312-24; PMID:21239359; http://dx.doi.org/10.1310/hct1106-312.
22. Buzón MJ, Massanella M, Llibre JM, Esteve A, Dahl V, Puertas MC, et al. HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects. Nat Med 2010; 16:460-5; PMID:20228817; http://dx.doi.org/10.1038/nm.2111.
23. Vallejo A, Gutierrez C, Hernandez-Novoa B, Diaz L, Madrid N, Abad-Fernandez M, et al. The effect of intensification with raltegravir on the HIV-1 reservoir of latently infected memory CD4 T cells in suppressed patients. AIDS 2012; 26:1885-94; PMID:22992577; http://dx.doi.org/10.1097/QAD. 0b013e3283584521.
24. Hütter G, Nowak D, Mossner M, Ganepola S, Müssig A, Allers K, et al. Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation. N Engl J Med 2009; 360:692-8; PMID:19213682; http://dx.doi.org/10.1056/NEJMoa0802905.
25. Lalezari J, Mitsuyasu R, Wang S, Lee G, Giedlin M, Tang W, et al. A Single Infusion of Zinc Finger Nuclease CCR5 Modified Autologous CD4 T Cells (SB-728-T) Increases CD4 Counts and Leads to Decrease in HIV Proviral Load in an Aviremic HIV-infected Subject. 19th Conference on Retroviruses and Opportunistic Infections. Seattle, 2012.
26. June C, Tebas P, Stein D, Mitsuyasu R, Lalezari J, Wang SS, et al. Induction of Acquired CCR5 Deficiency with Zinc Finger Nuclease-modified Autologous CD4 T Cells (SB-728-T) Correlates with Increases in CD4 Count and Effects on Viral Load in HIV+ Subjects. Conference on Retroviruses and Opportunistic Infections. Seattle, 2012.
27. Cillo A, Krishnan A, Mitsuyasu R, McMahon D, Li S, Rossi J, et al. Plasma Viremia and Cellular HIV-1 DNA Persist Despite Autologous Hematopoietic Stem Cell Transplantation for AIDS-related Lymphoma. 19th Conference on Retroviruses and Opportunistic Infections. Seattle, 2012.
28. Archin NM, Espeseth A, Parker D, Cheema M, Hazuda D, Margolis DM. Expression of latent HIV induced by the potent HDAC inhibitor suberoyl-anilide hydroxamic acid. AIDS Res Hum Retroviruses 2009; 25:207-12; PMID:19239360; http://dx.doi.org/10.1089/aid.2008.0191.
29. Contreras X, Schweneker M, Chen CS, McCune JM, Deeks SG, Martin J, et al. Suberoylanilide hydroxamic acid reactivates HIV from latently infected cells. J Biol Chem 2009; 284:6782-9; PMID:19136668; http://dx.doi.org/10.1074/jbc. M807898200.
30. Matalon S, Palmer BE, Nold M F, Furlan A, Kassu A, Fossati G, et al. The histone deacetylase inhibitor ITF2357 decreases surface CXCR4 and CCR5 expression on CD4(+) T-cells and monocytes and is superior to valproic acid for latent HIV-1 expression in vitro. J Acquir Immune Defic Syndr 2010; 54:1-9; PMID:20300007; http://dx.doi.org/10.1097/QAI.0b013e3181d3dca3.
31. Reuse S, Calao M, Kabeya K, Guiguen A, Gatot JS, Quivy V, et al. Synergistic activation of HIV-1 expression by deacetylase inhibitors and prostratin: implications for treatment of latent infection. PLoS One 2009; 4:e6093; PMID:19564922; http://dx.doi.org/10.1371/journal.pone.0006093.
32. Choi BS, Lee HS, Oh YT, Hyun YL, Ro S, Kim SS, et al. Novel histone deacetylase inhibitors CG05 and CG06 effectively reactivate latently infected HIV-1. AIDS 2010; 24:609-11; PMID:20154582; http://dx.doi.org/10.1097/QAD. 0b013e328333bfa1.
33. Ylisastigui L, Archin NM, Lehrman G, Bosch RJ, Margolis DM. Coaxing HIV-1 from resting CD4 T cells: histone deacetylase inhibition allows latent viral expression. AIDS 2004; 18:1101-8; PMID:15166525; http://dx.doi.org/10.1097/ 00002030-200405210-00003.
34. Yin H, Zhang Y, Zhou X, Zhu H. Histonedeacetylase inhibitor Oxamflatin increase HIV-1 transcription by inducing histone modification in latently infected cells. Mol Biol Rep 2011; 38:5071-8; PMID:21181272; http://dx.doi.org/10.1007/s11033-010-0653-6.
35. Wightman F, Ellenberg P, Churchill M, Lewin SR. HDAC inhibitors in HIV. Immunol Cell Biol 2012; 90:47-54; PMID:22083528; http://dx.doi.org/10.1038/icb. 2011.95.
36. Matalon S, Rasmussen TA, Dinarello CA. Histone deacetylase inhibitors for purging HIV-1 from the latent reservoir. Mol Med 2011; 17:466-72; PMID:21424110; http://dx.doi.org/10.2119/mol-med.2011.00076.
37. Lehrman G, Hogue IB, Palmer S, Jennings C, Spina CA, Wiegand A, et al. Depletion of latent HIV-1 infection in vivo: a proof-of-concept study. Lancet 2005; 366:549-55; PMID:16099290; http://dx.doi.org/10.1016/S0140-6736(05)67098- 5.
38. Archin NM, Cheema M, Parker D, Wiegand A, Bosch RJ, Coffin JM, et al. Antiretroviral intensification and valproic acid lack sustained effect on residual HIV-1 viremia or resting CD4+ cell infection. PLoS One 2010; 5:e9390; PMID:20186346; http://dx.doi.org/10.1371/journal.pone.0009390.
39. Archin NM, Eron JJ, Palmer S, Hartmann-Duff A, Martinson JA, Wiegand A, et al. Valproic acid without intensified antiviral therapy has limited impact on persistent HIV infection of resting CD4+ T cells. AIDS 2008; 22:1131-5; PMID:18525258; http://dx.doi.org/10.1097/QAD.0b013e3282fd6df4.
40. Archin NM, Liberty AL, Kashuba AD, Choudhary SK, Kuruc JD, Crooks AM, et al. Administration of vorino-stat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature 2012; 487:482-5; PMID:22837004; http://dx.doi.org/10.1038/nature11286.
41. Wang FX, Xu Y, Sullivan J, Souder E, Argyris EG, Acheampong EA, et al. IL-7 is a potent and proviral strain-specific inducer of latent HIV-1 cellular reservoirs of infected individuals on virally sup-pressive HAART. J Clin Invest 2005; 115:128-37; PMID:15630452.
42. Lehrman G, Ylisastigui L, Bosch RJ, Margolis DM. Interleukin-7 induces HIV type 1 outgrowth from peripheral resting CD4+ T cells. J Acquir Immune Defic Syndr 2004; 36:1103-4; PMID:15247565; http://dx.doi.org/10.1097/00126334- 200408150-00015.
43. Xing S, Bullen CK, Shroff NS, Shan L, Yang HC, Manucci JL, et al. Disulfiram reactivates latent HIV-1 in a Bcl-2-transduced primary CD4+ T cell model without inducing global T cell activation. J Virol 2011; 85:6060-4; PMID:21471244; http://dx.doi.org/10.1128/JVI.02033-10.
44. Biancotto A, Grivel JC, Gondois-Rey F, Bettendroffer L, Vigne R, Brown S, et al. Dual role of prostra-tin in inhibition of infection and reactivation of human immunodeficiency virus from latency in primary blood lymphocytes and lymphoid tissue. J Virol 2004; 78:10507-15; PMID:15367617; http://dx.doi.org/10. 1128/JVI.78.19.10507-10515.2004.
45. Kulkosky J, Culnan DM, Roman J, Dornadula G, Schnell M, Boyd MR, et al. Prostratin: activation of latent HIV-1 expression suggests a potential inductive adjuvant therapy for HAART. Blood 2001; 98:3006-15; PMID:11698284; http://dx.doi.org/10.1182/blood.V98.10.3006.
46. Williams SA, Chen LF, Kwon H, Fenard D, Bisgrove D, Verdin E, et al. Prostratin antagonizes HIV latency by activating NF-kappaB. J Biol Chem 2004; 279:42008-17; PMID:15284245; http://dx.doi.org/10.1074/jbc.M402124200.
47. Shan L, Deng K, Shroff NS, Durand CM, Rabi SA, Yang HC, et al. Stimulation of HIV-1-specific cytolytic T lymphocytes facilitates elimination of latent viral reservoir after virus reactivation. Immunity 2012; 36:491-501; PMID:22406268; http://dx.doi.org/10.1016/j.immuni.2012.01.014.
48. Persaud D, Luzuriaga K, Ziemniak C, Muresan P, Greenough T, Fenton T, et al. Effect of therapeutic HIV recombinant poxvirus vaccines on the size of the resting CD4+ T-cell latent HIV reservoir. AIDS 2011; 25:2227-34; PMID:21918423; http://dx.doi.org/10.1097/QAD.0b013e32834cdaba.
49. Wang L, de Zoeten EF, Greene MI, Hancock WW. Immunomodulatory effects of deacetylase inhibitors: therapeutic targeting of FOXP3+ regulatory T cells. Nat Rev Drug Discov 2009; 8:969-81; PMID:19855427.
50. Verdin E, Paras P Jr., Van Lint C. Chromatin disruption in the promoter of human immunodeficiency virus type 1 during transcriptional activation. EMBO J 1993; 12:3249-59; PMID:8344262.
51. Van Lint C, Emiliani S, Ott M, Verdin E. Transcriptional activation and chromatin remodeling of the HIV-1 promoter in response to histone acetyla-tion. EMBO J 1996; 15:1112-20; PMID:8605881.
52. Coull JJ, Romerio F, Sun JM, Volker JL, Galvin KM, Davie JR, et al. The human factors YY1 and LSF repress the human immunodeficiency virus type 1 long terminal repeat via recruitment of histone deacetylase 1. J Virol 2000; 74:6790-9; PMID:10888618; http://dx.doi.org/10.1128/JVI.74.15.6790-6799.2000.
53. Williams SA, Chen LF, Kwon H, Ruiz-Jarabo CM, Verdin E, Greene WC. NF-kappaB p50 promotes HIV latency through HDAC recruitment and repression of transcriptional initiation. EMBO J 2006; 25:139-49; PMID:16319923; http://dx.doi.org/10.1038/sj.emboj.7600900.
54. Imai K, Okamoto T. Transcriptional repression of human immunodeficiency virus type 1 by AP-4. J Biol Chem 2006; 281:12495-505; PMID:16540471; http://dx.doi.org/10.1074/jbc.M511773200.
55. Jiang G, Espeseth A, Hazuda DJ, Margolis DM. c-Myc and Sp1 contribute to proviral latency by recruiting histone deacetylase 1 to the human immunodeficiency virus type 1 promoter. J Virol 2007; 81:10914-23; PMID:17670825; http://dx.doi.org/10.1128/JVI.01208-07.
56. Lusic M, Marcello A, Cereseto A, Giacca M. Regulation of HIV-1 gene expression by histone acetylation and factor recruitment at the LTR promoter. EMBO J 2003; 22:6550-61; PMID:14657027; http://dx.doi.org/10.1093/emboj/cdg631.
57. Tyagi M, Karn J. CBF-1 promotes transcriptional silencing during the establishment of HIV-1 latency. EMBO J 2007; 26:4985-95; PMID:18007589; http://dx.doi.org/10.1038/sj.emboj.7601928.
58. Keedy KS, Archin NM, Gates AT, Espeseth A, Hazuda DJ, Margolis DM. A limited group of class I histone deacetylases acts to repress human immunodeficiency virus type 1 expression. J Virol 2009; 83:4749-56; PMID:19279091; http://dx.doi.org/10.1128/JVI.02585-08.
59. Huber K, Doyon G, Plaks J, Fyne E, Mellors JW, Sluis-Cremer N. Inhibitors of histone deacetylases: correlation between isoform specificity and reactivation of HIV type 1 (HIV-1) from latently infected cells. J Biol Chem 2011; 286:22211-8; PMID:21531716; http://dx.doi.org/10.1074/jbc.M110.180224.
60. Grozinger CM, Hassig CA, Schreiber SL. Three proteins define a class of human histone deacetylases related to yeast Hda1p. Proc Natl Acad Sci U S A 1999; 96:4868-73; PMID:10220385; http://dx.doi.org/10.1073/pnas.96.9.4868.
61. Choudhary C, Kumar C, Gnad F, Nielsen ML, Rehman M, Walther TC, et al. Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science 2009; 325:834-40; PMID:19608861; http://dx.doi.org/10.1126/ science.1175371.
62. Minucci S, Pelicci PG. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 2006; 6:38-51; PMID:16397526; http://dx.doi.org/10.1038/nrc1779.
63. Routy J P, Tremblay CL, Angel JB, Trottier B, Rouleau D, Baril JG, et al. Valproic acid in association with highly active antiretroviral therapy for reducing systemic HIV-1 reservoirs: results from a multicentre randomized clinical study. HIV Med 2012; 13:291-6; PMID:22276680; http://dx.doi.org/10. 1111/j.1468-1293.2011.00975.x.
64. Khan N, Jeffers M, Kumar S, Hackett C, Boldog F, Khramtsov N, et al. Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors. Biochem J 2008; 409:581-9; PMID:17868033; http://dx.doi.org/10.1042/BJ20070779.
65. Wightman F, Ramanayake S, Saleh S, Solomon A, Dear A, Shebu-Xhilaga M, et al. Potency and Toxicity of HDACi and Other Immune Activators in Inducing HIV Production Using a Primary Resting T Cell Model of HIV Latency. Conference on Retroviruses and Opportunistic Infections. Boston, 2011.
66. Blazkova J, Chun TW, Belay BW, Murray D, Justement JS, Funk EK, et al. Effect of histone deacetylase inhibitors on HIV production in latently infected, resting CD4(+) T cells from infected individuals receiving effective antiretroviral therapy. J Infect Dis 2012; 206:765-9; PMID:22732922; http://dx.doi.org/10.1093/infdis/jis412.
67. Rasmussen TA, Søgaard O, Melchjorsen J, Brinkmann C, Østergaard L, Dinarello CA, et al. HDACi LBH589 Stimulates HIV-1 Expression More Potently than Other HDACi in Clinical Use and Disrupts HIV Latency at Clinically Achievable Concentrations. Conference on Retroviruses and Opportunistic Infections. Seattle, 2012.
68. Furlan A, Monzani V, Reznikov LL, Leoni F, Fossati G, Modena D, et al. Pharmacokinetics, safety and inducible cytokine responses during a phase 1 trial of the oral histone deacetylase inhibitor ITF2357 (givino-stat). Mol Med 2011; 17:353-62; PMID:21365126; http://dx.doi.org/10.2119/molmed.2011.00020.
69. Leoni F, Fossati G, Lewis EC, Lee JK, Porro G, Pagani P, et al. The histone deacetylase inhibitor ITF2357 reduces production of pro-inflammatory cytokines in vitro and systemic inflammation in vivo. Mol Med 2005; 11:1-15; PMID:16557334; http://dx.doi.org/10.2119/2006-00005.Dinarello.
70. Vojinovic J, Dinarello CA, Damjano N, Oldoni T. Safety and Efficacy of Oral ITF2357 in Patients with Active Systemic Onset Juvenile Idiopathic Arthritis (SOJIA)-Results of a Phase II, Open Label, International, Multicentre Clinical Trial. Abstract 2008 Annual Scientific Meeting, American College of Rheumatology 2008.
71. Kuller LH, Tracy R, Belloso W, De Wit S, Drummond F, Lane HC, et al.; INSIGHT SMART Study Group. Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med 2008; 5:e203; PMID:18942885; http://dx.doi.org/10.1371/journal.pmed.0050203.
72. Neuhaus J, Jacobs DR Jr., Baker JV, Calmy A, Duprez D, La Rosa A, et al. Markers of inflammation, coagulation, and renal function are elevated in adults with HIV infection. J Infect Dis 2010; 201:1788-95; PMID:20446848; http://dx.doi.org/10.1086/652749.
73. Phillips AN, Gazzard B, Gilson R, Easterbrook P, Johnson M, Walsh J, et al.; UK Collaborative HIV Cohort Study. Rate of AIDS diseases or death in HIV-infected antiretroviral therapy-naive individuals with high CD4 cell count. AIDS 2007; 21:1717-21; PMID:17690569; http://dx.doi.org/10.1097/QAD. 0b013e32827038bf.
74. Deeks SG, Phillips AN. HIV infection, antiretroviral treatment, ageing, and non-AIDS related morbidity. BMJ 2009; 338:a3172; PMID:19171560; http://dx.doi.org/10.1136/bmj.a3172.
75. Prince HM, Bishton MJ, Johnstone RW. Panobinostat (LBH589): a potent pan-deacetylase inhibitor with promising activity against hematologic and solid tumors. Future Oncol 2009; 5:601-12; PMID:19519200; http://dx.doi.org/10.2217/ fon.09.36.
76. Ying H, Zhang Y, Lin S, Han Y, Zhu HZ. Histone deacetylase inhibitor Scriptaid reactivates latent HIV-1 promoter by inducing histone modification in in vitro latency cell lines. Int J Mol Med 2010; 26:265-72; PMID:20596607.
77. Sahu GK, Cloyd MW. Latent HIV in primary T lymphocytes is unresponsive to histone deacetylase inhibitors. Virol J 2011; 8:400; PMID:21838863; http://dx.doi.org/10.1186/1743-422X-8-400.
78. Archin NM, Keedy KS, Espeseth A, Dang H, Hazuda DJ, Margolis DM. Expression of latent human immunodeficiency type 1 is induced by novel and selective histone deacetylase inhibitors. AIDS 2009; 23:1799-806; PMID:19590405; http://dx.doi.org/10.1097/QAD.0b013e32832ec1dc.
79. Lin S, Zhang Y, Ying H, Zhu H. HIV-1 reactivation induced by apicidin involves histone modification in latently infected cells. Curr HIV Res 2011; 9:202-8; PMID:21631428.
80. Victoriano A F, Imai K, Togami H, Ueno T, Asamitsu K, Suzuki T, et al. Novel histone deacetylase inhibitor NCH-51 activates latent HIV-1 gene expression. FEBS Lett 2011; 585:1103-11; PMID:21402072; http://dx.doi.org/10. 1016/j.febslet.2011.03.017.
81. Furumai R, Matsuyama A, Kobashi N, Lee KH, Nishiyama M, Nakajima H, et al. FK228 (depsi-peptide) as a natural prodrug that inhibits class I histone deacetylases. Cancer Res 2002; 62:4916-21; PMID:12208741.
82. Hancock WW, Akimova T, Beier UH, Liu Y, Wang L. HDAC inhibitor therapy in autoimmunity and transplantation. Ann Rheum Dis 2012; 71(Suppl 2):i46-54; PMID:22460138; http://dx.doi.org/10.1136/annrheumdis-2011-200593.
83. Akimova T, Beier UH, Liu Y, Wang L, Hancock W W. Histone/protein deacetylases and T-cell immune responses. Blood 2012; 119:2443-51; PMID:22246031; http://dx.doi.org/10.1182/blood-2011-10-292003.
84. Tao R, de Zoeten E F, Ozkaynak E, Chen C, Wang L, Porrett PM, et al. Deacetylase inhibition promotes the generation and function of regulatory T cells. Nat Med 2007; 13:1299-307; PMID:17922010; http://dx.doi.org/10.1038/ nm1652.
85. Leng C, Gries M, Ziegler J, Lokshin A, Mascagni P, Lentzsch S, et al. Reduction of graft-versus-host disease by histone deacetylase inhibitor suberonyl-anilide hydroxamic acid is associated with modulation of inflammatory cytokine milieu and involves inhibition of STAT1. Exp Hematol 2006; 34:776-87; PMID:16728283; http://dx.doi.org/10.1016/j.exphem.2006.02.014.
86. Wang D, Iclozan C, Liu C, Xia C, Anasetti C, Yu XZ. LBH589 enhances T cell activation in vivo and accelerates graft-versus-host disease in mice. Biol Blood Marrow Transplant 2012; 18:1182-90, e1; PMID:22698484; http://dx.doi.org/10.1016/j.bbmt.2012.06.002.
87. Dawson MA, Kouzarides T, Huntly BJ. Targeting epigenetic readers in cancer. N Engl J Med 2012; 367:647-57; PMID:22894577; http://dx.doi.org/10.1056/ NEJMra1112635.
88. Chun T W, Engel D, Mizell SB, Hallahan C W, Fischette M, Park S, et al. Effect of interleukin-2 on the pool of latently infected, resting CD4+ T cells in HIV-1-infected patients receiving highly active anti-retroviral therapy. Nat Med 1999; 5:651-5; PMID:10371503; http://dx.doi.org/10.1038/9498.
89. Chun TW, Davey RT Jr., Engel D, Lane HC, Fauci AS. Re-emergence of HIV after stopping therapy. Nature 1999; 401:874-5; PMID:10553903; http://dx.doi.org/10.1038/44755.
90. Dybul M, Hidalgo B, Chun TW, Belson M, Migueles SA, Justement JS, et al. Pilot study of the effects of intermittent interleukin-2 on human immunodeficiency virus (HIV)-specific immune responses in patients treated during recently acquired HIV infection. J Infect Dis 2002; 185:61-8; PMID:11756982; http://dx.doi.org/10.1086/338123.
91. Stellbrink HJ, van Lunzen J, Westby M, O'Sullivan E, Schneider C, Adam A, et al. Effects of interleukin-2 plus highly active antiretroviral therapy on HIV-1 replication and proviral DNA (COSMIC trial). AIDS 2002; 16:1479-87; PMID:12131185; http://dx.doi.org/10.1097/00002030-200207260-00004.
92. van Praag RM, Prins JM, Roos M T, Schellekens P T, Ten Berge IJ, Yong SL, et al. OKT3 and IL-2 treatment for purging of the latent HIV-1 reservoir in vivo results in selective long-lasting CD4+ T cell depletion. J Clin Immunol 2001; 21:218-26; PMID:11403229; http://dx.doi.org/10.1023/A:1011091300321.
93. Levy Y, Lacabaratz C, Weiss L, Viard J P, Goujard C, Lelièvre JD, et al. Enhanced T cell recovery in HIV-1-infected adults through IL-7 treatment. J Clin Invest 2009; 119:997-1007; PMID:19287090.
94. Sereti I, Dunham RM, Spritzler J, Aga E, Proschan MA, Medvik K, et al.; ACTG 5214 Study Team. IL-7 administration drives T cell-cycle entry and expansion in HIV-1 infection. Blood 2009; 113:6304-14; PMID:19380868; http://dx.doi.org/10.1182/blood-2008-10-186601.
95. Imamichi H, Degray G, Asmuth DM, Fischl MA, Landay AL, Lederman MM, et al. HIV-1 viruses detected during episodic blips following interleukin-7 administration are similar to the viruses present before and after interleukin-7 therapy. AIDS 2011; 25:159-64; PMID:21124203; http://dx.doi.org/10.1097/QAD. 0b013e328340a270.
96. Bosque A, Famiglietti M, Weyrich AS, Goulston C, Planelles V. Homeostatic proliferation fails to efficiently reactivate HIV-1 latently infected central memory CD4+ T cells. PLoS Pathog 2011; 7:e1002288; PMID:21998586; http://dx.doi.org/10.1371/journal.ppat.1002288.
97. Lévy Y, Sereti I, Tambussi G, Routy J P, Lelièvre JD, Delfraissy J F, et al. Effects of recombinant human interleukin 7 on T-cell recovery and thymic output in HIV-infected patients receiving antiretroviral therapy: results of a phase I/IIa randomized, placebo-controlled, multicenter study. Clin Infect Dis 2012; 55:291-300; PMID:22550117; http://dx.doi.org/10. 1093/cid/cis383.
98. Thibault S, Imbeault M, Tardif MR, Tremblay MJ. TLR5 stimulation is sufficient to trigger reactivation of latent HIV-1 provirus in T lymphoid cells and activate virus gene expression in central memory CD4+ T cells. Virology 2009; 389:20-5; PMID:19447460; http://dx.doi.org/10.1016/j.virol.2009.04.019.
99. Schlaepfer E, Audigé A, Joller H, Speck R F. TLR7/8 triggering exerts opposing effects in acute versus latent HIV infection. J Immunol 2006; 176:2888-95; PMID:16493046.
100. Schlaepfer E, Speck R F. TLR8 activates HIV from latently infected cells of myeloid-monocytic origin directly via the MAPK pathway and from latently infected CD4+ T cells indirectly via TNF-α. J Immunol 2011; 186:4314-24; PMID:21357269; http://dx.doi.org/10.4049/jimmunol.1003174.
101. Scheller C, Ullrich A, Lamla S, Dittmer U, Rethwilm A, Koutsilieri E. Dual activity of phosphorothioate CpG oligodeoxynucleotides on HIV: reactivation of latent provirus and inhibition of productive infection in human T cells. Ann.N.Y. Acad.Sci. 2006; 1091:540-7; http://dx.doi.org/10.1196/annals.1378.095.
102. Scheller C, Ullrich A, McPherson K, Hefele B, Knöferle J, Lamla S, et al. CpG oligodeoxynucleotides activate HIV replication in latently infected human T cells. J Biol Chem 2004; 279:21897-902; PMID:15016800; http://dx.doi.org/10.1074/jbc.M311609200.
103. Søgaard OS, Lohse N, Harboe ZB, Offersen R, Bukh AR, Davis HL, et al. Improving the immuno-genicity of pneumococcal conjugate vaccine in HIV-infected adults with a toll-like receptor 9 agonist adjuvant: a randomized, controlled trial. Clin Infect Dis 2010; 51:42-50; PMID:20504165; http://dx.doi.org/10.1086/653112.
104. Berg RK, Melchjorsen J, Rintahaka J, Diget E, Søby S, Horan KA, et al. Genomic HIV RNA induces innate immune responses through RIG-I-dependent sensing of secondary-structured RNA. PLoS One 2012; 7:e29291; PMID:22235281; http://dx.doi.org/10.1371/journal.pone.0029291.
105. Ramsdell JS, Pettit GR, Tashjian AH Jr. Three activators of protein kinase C, bryostatins, dioleins, and phorbol esters, show differing specificities of action on GH4 pituitary cells. J Biol Chem 1986; 261:17073-80; PMID:3465727.
106. Mehla R, Bivalkar-Mehla S, Zhang R, Handy I, Albrecht H, Giri S, et al. Bryostatin modulates latent HIV-1 infection via PKC and AMPK signaling but inhibits acute infection in a receptor independent manner. PLoS One 2010; 5:e11160; PMID:20585398; http://dx.doi.org/10.1371/journal.pone.0011160.
107. Kovochich M, Marsden MD, Zack JA. Activation of latent HIV using drug-loaded nanoparticles. PLoS One 2011; 6:e18270; PMID:21483687; http://dx.doi.org/10.1371/journal.pone.0018270.
108. DeChristopher BA, Loy BA, Marsden MD, Schrier AJ, Zack JA, Wender PA. Designed, synthetically accessible bryostatin analogues potently induce activation of latent HIV reservoirs in vitro. Nat Chem 2012; 4:705-10; PMID:22914190; http://dx.doi.org/10.1038/nchem.1395.
109. Rullas J, Bermejo M, García-Pérez J, Beltán M, González N, Hezareh M, et al. Prostratin induces HIV activation and downregulates HIV receptors in peripheral blood lymphocytes. Antivir Ther 2004; 9:545-54; PMID:15456086.
110. Pérez M, de Vinuesa AG, Sanchez-Duffhues G, Marquez N, Bellido ML, Muñoz-Fernandez MA, et al. Bryostatin-1 synergizes with histone deacetylase inhibitors to reactivate HIV-1 from latency. Curr HIV Res 2010; 8:418-29; PMID:20636281; http://dx.doi.org/10.2174/157016210793499312.
111. Yang HC, Xing S, Shan L, O'Connell K, Dinoso J, Shen A, et al. Small-molecule screening using a human primary cell model of HIV latency identifies compounds that reverse latency without cellular activation. J Clin Invest 2009; 119:3473-86; PMID:19805909.
112. Doyon G, Zerbato J, Mellors J W, Sluis-Cremer N. Disulfiram reactivates latent HIV-1 expression through depletion of the phosphatase and tensin homolog (PTEN). AIDS 2012.
113. Spivak A, Andrade A, Hoh H, Bacchetti P, Eisele E, Buckheit R, et al. Safety and Feasibility of Using Disulfiram to Enhance HIV Transcription among Long-term ARV-treated Adults: Preliminary Results from a Pilot Study. 19th Conference on Retroviruses and Opportunistic Infections. Seattle, 2012.
114. Imai K, Togami H, Okamoto T. Involvement of histone H3 lysine 9 (H3K9) methyltransferase G9a in the maintenance of HIV-1 latency and its reactivation by BIX01294. J Biol Chem 2010; 285:16538-45; PMID:20335163; http://dx.doi.org/ 10.1074/jbc.M110.103531.
115. Bouchat S, Gatot JS, Kabeya K, Cardona C, Colin L, Herbein G, et al. Histone methyltransferase inhibitors induce HIV-1 recovery in resting CD4(+) T cells from HIV-1-infected HAART-treated patients. AIDS 2012; 26:1473-82; PMID:22555163; http://dx.doi.org/10.1097/QAD.0b013e32835535f5.
116. Andreeff M, Stone R, Michaeli J, Young CW, Tong W P, Sogoloff H, et al. Hexamethylene bisacetamide in myelodysplastic syndrome and acute myelogenous leukemia: a phase II clinical trial with a differentiation-inducing agent. Blood 1992; 80:2604-9; PMID:1421378.
117. Klichko V, Archin N, Kaur R, Lehrman G, Margolis D. Hexamethylbisacetamide remodels the human immunodeficiency virus type 1 (HIV-1) promoter and induces Tat-independent HIV-1 expression but blunts cell activation. J Virol 2006; 80:4570-9; PMID:16611917; http://dx.doi.org/10.1128/ JVI.80.9.4570-4579.2006.
118. Choudhary SK, Archin NM, Margolis DM. Hexamethylbisacetamide and disruption of human immunodeficiency virus type 1 latency in CD4(+) T cells. J Infect Dis 2008; 197:1162-70; PMID:18419522; http://dx.doi.org/10.1086/529525.
119. Sigal A, Kim J T, Balazs AB, Dekel E, Mayo A, Milo R, et al. Cell-to-cell spread of HIV permits ongoing replication despite antiretroviral therapy. Nature 2011; 477:95-8; PMID:21849975; http://dx.doi.org/10.1038/nature10347.
120. Hersperger AR, Pereyra F, Nason M, Demers K, Sheth P, Shin LY, et al. Perforin expression directly ex vivo by HIV-specific CD8 T-cells is a correlate of HIV elite control. PLoS Pathog 2010; 6:e1000917; PMID:20523897; http://dx.doi.org/10.1371/journal.ppat.1000917.